The Future of Drug Discovery
Who Decides Which Diseases to Treat?
- Tamas Bartfai, PhD, The Scripps Research Institute, La Jolla, CA Harold L. Dorris Neurological Research Center and Scripps Research Institute, La Jolla, California, USA
- Graham Lees, PhD, Publishing Consultant, Corpus Alienum Oy, Finland
AudienceBiomedical researchers involved in drug discovery in industry and academic settings, physicians, patient advocacy groups, health economists and regulatory officials
- Published: May 2013
- Imprint: ACADEMIC PRESS
- ISBN: 978-0-12-407180-3
"This book reviews in exquisite detail the drug development process from the initial inception of an idea through the life cycle of a new drug entity. The authors also spend an appropriate amount of time on the role of government-funded research programs along with the role of medium and small biotechnology companies in the drug treatment of diseasesâ¦Summing Up: Highly recommended."--CHOICE Reviews Online, December 2013
"Bartfai and Lees describe the looming crisis in health careâ¦They target society in general as their audience, because of the need for the public to understand what is happening and why they should be concerned. The book is a compendium of data and analysis and there are many tables and figures supporting the text."--Reference and Research Book News, August 2013
"A remarkable compendium of hard data and wise prescription for the pharmaceutical industry."--Michael S. Brown, 1985 Novel Laureate in Medicine or Physiology, UT Southwestern Medical Center "This is an extraordinary, insightful and provocative book that should be read by all those concerned by the progress of biomedicine, from scientists to politicians." - Jean-Pierre Changeux, CollÃ¨ge de France and lâInstitut Pasteur "Bartfai and Lees raise critical issues confronting the search for new medicines. Their analysis is cogent, and their proposals thoughtful and thought provoking. For anyone curious about where new medicines come from, and what it will take for the BioPharma industry to bring new treatments to patients with Alzheimer's disease, diabetes, depression, cancer, and more, this is a must read." - Michael D. Ehlers, Senior VP Pfizer and CSO Neuroscience, former Howard Hughes Investigator, Duke University "This book is a must read for students, prescribing physicians, academic and industry researchers, analysts, patient groups, business and science journalists, and importantly, Policy Makers. More than ever before, drug development is a complex scientific, industrial and societal endeavour that needs the combined attention of Governments, Academics and Big Pharma; it cannot be left to Wall Street alone." - Daniel Hoyer, Chair, Department of Pharmacology, University of Melbourne, former Novartis Leading Scientist
Table of Contents
00 - Introduction for the non-specialist
01 - Why there will be new drugs despite the ongoing âcrisisâ of drug development in big pharma
02 - The need for medicine grows
03 - Medicines are becoming better
04 - Which diseases do we want to treat?
05 - Therapeutic Areas: strategically important diseases for the future
06 - Blockbuster proprietary drugs versus generic drugs
07 - Why is pharma a special industry?
08 - Diagnosing towards personalized medicine
09 - Personalized medicine
10 - How much can drugs cost?
11 - Modeling Drug Discovery until 2025
12 - Drug development models between 2010 and 2025